PSTX Stock Price, Poseida Therapeutics, . Quote, Chart

Market Summary

USD2.79+0.02

Market Closed

0.72%

PSTX Stock Price

View Fullscreen

PSTX RSI Chart

PSTX Valuation

Market Cap

269.2M

Price/Earnings (Trailing)

-2.18

Price/Sales (Trailing)

4.16

EV/EBITDA

-55.15

Price/Free Cashflow

-2.83

PSTX Price/Sales (Trailing)

PSTX Profitability

EBT Margin

-29.96%

Return on Equity

-119.02%

Return on Assets

-45.07%

Free Cashflow Yield

-35.38%

PSTX Fundamentals

PSTX Revenue

Revenue (TTM)

64.7M

Rev. Growth (Yr)

148.68%

Rev. Growth (Qtr)

167.27%

PSTX Earnings

Earnings (TTM)

-123.4M

Earnings Growth (Yr)

23.92%

Earnings Growth (Qtr)

20.23%

Breaking Down PSTX Revenue

Last 7 days

36.1%

Last 30 days

-3.8%

Last 90 days

-20.1%

Trailing 12 Months

2.6%

How does PSTX drawdown profile look like?

PSTX Financial Health

Current Ratio

3.18

Debt/Equity

0.56

Debt/Cashflow

-1.57

PSTX Investor Care

Shares Dilution (1Y)

11.51%

Diluted EPS (TTM)

-1.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	139.4M	156.7M	49.8M	64.7M
2022	56.1M	80.9M	105.7M	130.5M
2021	0	0	0	31.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Poseida Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	rizvi syed ali-aamir	acquired	-	-	185,000	chief medical officer
Mar 01, 2024	mylet johanna	sold (taxes)	-74,715	4.13	-18,091	chief financial officer
Mar 01, 2024	warner brent	acquired	-	-	80,743	president, gene therapy
Mar 01, 2024	warner brent	sold (taxes)	-147,602	4.13	-35,739	president, gene therapy
Mar 01, 2024	mylet johanna	acquired	-	-	80,743	chief financial officer
Mar 01, 2024	gergen mark j	sold (taxes)	-141,068	4.13	-34,157	executive chairman
Mar 01, 2024	leonhardt harry j	acquired	-	-	80,743	gc & chief compliance officer
Mar 01, 2024	leonhardt harry j	sold (taxes)	-67,343	4.13	-16,306	gc & chief compliance officer
Feb 01, 2024	gergen mark j	sold (taxes)	-160,822	3.41	-47,162	executive chairman
Jan 02, 2024	gergen mark j	acquired	-	-	125,000	executive chairman

Which funds bought or sold PSTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	sold off	-100	-383,077	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	41.00	41.00	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-22,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-11.99	-127,061	645,605	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	-40,000	302,000	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.35	-13,000	7,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	35,583	121,998	-%
Apr 16, 2024	VOISARD ASSET MANAGEMENT GROUP, INC.	unchanged	-	-46.00	862	-%
Apr 16, 2024	MCF Advisors LLC	unchanged	-	-41,994	788,008	0.06%

Are Funds Buying or Selling PSTX?

Are funds buying PSTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PSTX

No. of Funds

Unveiling Poseida Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 31, 2024	blackrock inc.	5.3%	5,031,173	SC 13G
Aug 14, 2023	astellas us llc	8.7%	-	SC 13D
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Apr 25, 2022	pentwater capital management lp	7.94%	4,967,227	SC 13D/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 12, 2021	novartis pharma ag	9.6%	5,908,089	SC 13G
Feb 08, 2021	fmr llc	-	0	SC 13G/A
Feb 03, 2021	malin life sciences holdings ltd	14.9%	9,188,125	SC 13G
Dec 28, 2020	pentwater capital management lp	8.03%	4,967,227	SC 13D

Recent SEC filings of Poseida Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 01, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 17, 2024	8-K	Current Report
Apr 08, 2024	8-K	Current Report
Apr 08, 2024	S-3	S-3
Apr 03, 2024	3	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 07, 2024	10-K	Annual Report

Peers (Alternatives to Poseida Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Poseida Therapeutics, Inc. News

Latest updates

Poseida Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	167.3%	24,995,000	9,352,000	20,013,000	10,343,000	10,051,000	116,306,000	2,700,000	1,435,000	-
Operating Expenses	11.7%	50,905,000	45,574,000	47,868,000	49,859,000	43,271,500	44,526,000	44,245,000	58,396,000	48,716,000
S&GA Expenses	9.5%	8,859,500	8,092,000	8,676,000	11,807,000	9,367,500	9,389,000	9,237,000	9,546,000	9,609,000
R&D Expenses	12.2%	42,045,500	37,482,000	39,192,000	38,052,000	33,904,000	35,137,000	35,008,000	48,850,000	39,107,000
EBITDA Margin	81.8%	-0.08	-0.44	-0.31	-0.38	-0.41	-0.21	-1.68	-2.43	-3.75
Interest Expenses	1.4%	2,266,500	2,236,000	2,141,000	2,028,000	3,518,000	1,775,000	-1,543,000	1,077,000	840,000
Income Taxes	-100.0%	-	107,000	-	-	292,000	252,000	-	-	-
Earnings Before Taxes	20.0%	-25,349,000	-31,671,000	-	-	-33,026,000	70,661,000	-43,036,000	-58,057,000	1,469,000
EBT Margin	59.8%	-0.30	-0.75	-0.40	-0.46	-0.49	-0.27	-1.76	-2.58	-4.00
Net Income	20.2%	-25,349,000	-31,778,000	-27,456,000	-38,847,000	-33,318,000	70,409,000	-43,036,000	-58,057,000	1,443,000
Net Income Margin	27.8%	-1.91	-2.64	-0.19	-0.32	-0.49	-0.28	-1.76	-2.58	-4.00
Free Cashflow	-508.6%	-29,053,000	7,111,000	-34,479,000	-38,789,000	2,115,000	60,175,000	-40,947,000	-52,067,000	8,303,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-9.4%	274	302	281	314	352	380	205	248	269	262	299	333	371	405	226	147
Current Assets	-10.4%	226	253	230	261	299	325	148	191	214	205	240	274	314	347	173	127
Cash Equivalents	74.4%	44.00	26.00	50.00	40.00	81.00	165	63.00	184	206	198	200	170	84.00	66.00	147	88.00
Net PPE	-6.5%	19.00	20.00	21.00	22.00	22.00	22.00	23.00	22.00	22.00	22.00	23.00	23.00	23.00	24.00	22.00	11.00
Goodwill	0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	-4.7%	170	179	146	156	164	164	140	144	113	112	113	106	110	109	105	74.00
Current Liabilities	-7.3%	71.00	77.00	50.00	49.00	54.00	49.00	40.00	44.00	43.00	32.00	32.00	28.00	30.00	30.00	29.00	22.00
Long Term Debt	0.2%	59.00	58.00	58.00	58.00	58.00	58.00	58.00	58.00	29.00	29.00	29.00	26.00	29.00	29.00	29.00	26.00
LT Debt, Non Current	0.2%	59.00	58.00	58.00	58.00	58.00	58.00	58.00	58.00	29.00	29.00	29.00	26.00	29.00	29.00	29.00	26.00
Shareholder's Equity	-16.1%	104	124	135	158	188	216	66.00	104	156	150	187	227	262	296	-	262
Retained Earnings	-4.5%	-594	-568	-537	-509	-470	-437	-508	-464	-406	-408	-365	-320	-281	-245	-211	-152
Additional Paid-In Capital	0.7%	698	693	673	667	659	654	574	569	563	558	552	548	544	542	6.00	3.00
Shares Outstanding	0.1%	96.00	96.00	87.00	87.00	86.00	67.00	63.00	63.00	63.00	62.00	62.00	62.00	-	-	-	-
Float	-	-	-	123	-	-	-	100	-	-	-	357	-	-	-	516	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	-464.4%	-28,744	7,888	-33,306	-38,005	2,403	61,878	-39,729	-51,324	8,473	-40,872	-31,088	-39,056	-30,315	-29,327	-30,801	-22,885	-	-	-
Share Based Compensation	-1.1%	5,063	5,117	5,474	7,480	4,548	4,277	5,234	4,867	4,349	4,151	4,742	3,462	2,200	1,895	1,616	1,509	-	-	-
Cashflow From Investing	201.0%	47,713	-47,237	43,073	-4,415	-85,890	-35,872	-80,829	-743	-195	37,135	60,919	124,525	47,972	-258,064	11,634	-5,973	-	-	-
Cashflow From Financing	-100.0%	-	14,941	-	1,186	58.00	75,838	32.00	29,231	236	1,855	67.00	360	38.00	206,529	103,028	4,346	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PSTX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Collaboration revenue	$ 64,703	$ 130,492
Operating expenses:
Research and development	156,772	152,899
General and administrative	37,435	37,539
Total operating expenses	194,207	190,438
Loss from operations	(129,504)	(59,946)
Other income (expense):
Interest expense	(8,671)	(6,370)
Other income, net	14,852	2,858
Net loss before income tax	(123,323)	(63,458)
Income tax expense	(107)	(544)
Net loss	(123,430)	(64,002)
Other comprehensive income (expense):
Unrealized gain (loss) on short-term investments	275	(149)
Comprehensive loss	$ (123,155)	$ (64,151)
Net loss per share attributable to common stockholders, basic	$ (1.37)	$ (0.89)
Net loss per share attributable to common stockholders, diluted	$ (1.37)	$ (0.89)
Weighted-average number of shares outstanding, basic	90,185,096	71,953,703
Weighted-average number of shares outstanding, diluted	90,185,096	71,953,703
Collaboration Revenue
Revenues:
Collaboration revenue	$ 64,703	$ 130,492

PSTX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 44,472	$ 81,378
Short-term investments	167,730	201,115
Accounts receivable	9,010	9,088
Prepaid expenses and other current assets	5,263	6,982
Total current assets	226,475	298,563
Property and equipment, net	19,055	21,586
Operating lease right-of-use assets	21,726	25,085
Intangible assets, net	1,320	1,320
Goodwill	4,228	4,228
Other long-term assets	1,081	1,055
Total assets	273,885	351,837
Current liabilities:
Accounts payable	3,267	2,228
Accrued expenses and other liabilities	31,092	26,068
Operating lease liabilities, current	5,951	5,866
Deferred revenue, current	31,008	19,723
Total current liabilities	71,318	53,885
Term debt	58,590	58,250
Deferred CIRM grant liability		3,992
Deferred revenue, non-current	16,780	21,333
Operating lease liabilities, non-current	20,882	24,636
Other long-term liabilities	2,614	2,146
Total liabilities	170,184	164,242
Commitments and Contingencies (Note 12)
Stockholders’ equity:
Common stock, $0.0001 par value: 250,000,000 shares authorized at December 31, 2023 and December 31, 2022; 95,636,553 and 85,964,161 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	10	9
Additional paid-in capital	697,856	658,596
Accumulated other comprehensive income (loss)	126	(149)
Accumulated deficit	(594,291)	(470,861)
Total stockholders’ equity	103,701	187,595
Total liabilities and stockholders’ equity	$ 273,885	$ 351,837

About Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

CEO	Mr. Mark J. Gergen J.D.
WEBSITE	https://poseida.com
INDUSTRY	Biotechnology
EMPLOYEES	348

Poseida Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Poseida Therapeutics, Inc.? What does PSTX stand for in stocks?

PSTX is the stock ticker symbol of Poseida Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Poseida Therapeutics, Inc. (PSTX)?

As of Thu May 02 2024, market cap of Poseida Therapeutics, Inc. is 269.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PSTX stock?

You can check PSTX's fair value in chart for subscribers.

What is the fair value of PSTX stock?

You can check PSTX's fair value in chart for subscribers. The fair value of Poseida Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Poseida Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PSTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Poseida Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether PSTX is over valued or under valued. Whether Poseida Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Poseida Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSTX.

What is Poseida Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, PSTX's PE ratio (Price to Earnings) is -2.18 and Price to Sales (PS) ratio is 4.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSTX PE ratio will change depending on the future growth rate expectations of investors.